Carna Biosciences, a leading provider of drug discovery supporting products and services, collaborate with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, to develop and commercialize small molecule protein kinase inhibitor programmes.
Under the terms of the agreement, facilitated by Johnson & Johnson Innovation, California and Asia Pacific, Carna Biosciences will receive an initial upfront payment and is eligible to receive additional milestone payments upon achievement of certain developmental, regulatory, and commercial milestones. Carna Biosciences will also be eligible to receive tiered royalties on the net sales of commercialized licensed products.
Carna has also established a vast collection of compound libraries consisting of kinase-focused and diverse molecules to maximize the success rate of screening. Carna’s drug discovery efforts are supported by Carna’s internally developed, proprietary profiling and screening technology, QuickScout, and by several other in-house drug discovery tools. QuickScout is one of the world’s largest biochemical kinase assay panels and enables the efficient development of small molecule inhibitors with potentially superior safety and efficacy profiles by providing valuable and comprehensive selectivity information.
Subscribe to PharmaTutor News Alerts by Email >>
